More payers are trying to rein in the use of antipsychotics in patients WITHOUT psychotic disorders

More payers are trying to rein in the use of antipsychotics in patients WITHOUT psychotic disorders.

Almost $6 BILLION a year is spent on Abilify alone.

Now the Choosing Wisely report and others are pointing out when the risks of antipsychotics are likely to outweigh their benefit.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote